| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.1...
Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing t...
Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing t...